Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential

J. Stalinska, E. Zimolag, N. A. Pianovich, A. Zapata, A. Lassak, M. Rak, M. Dean, D. Ucar-Bilyeu, D. Wyczechowska, F. Culicchia, L. Marrero, L. Del Valle, Jann N Sarkaria, F. Peruzzi, B. S. Jursic, K. Reiss

Research output: Contribution to journalArticle

Abstract

Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy. We have previously reported that fenofibrate in its unprocessed form (ester)accumulates in the mitochondria, inhibits mitochondrial respiration, and triggers a severe energy deficit and extensive glioblastoma cell death. However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARα agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death. To address these issues, we have made several chemical modifications in fenofibrate structure to increase its stability, water solubility, tissue penetration, and ultimately anticancer potential. Our data show that, in comparison to fenofibrate, four new compounds designated here as PP1, PP2, PP3, and PP4 have improved anticancer activity in vitro. Like fenofibrate, the compounds block mitochondrial respiration and trigger massive glioblastoma cell death in vitro. In addition, one of the lead compounds, PP1, has improved water solubility and is significantly more stable when exposed to human blood in comparison to fenofibrate. Importantly, mice bearing large intracranial glioblastoma tumors demonstrated extensive areas of tumor cell death within the tumor mass following oral administration of PP1, and the treated mice did not show any major signs of distress, and accumulated PP1 at therapeutically relevant concentrations in several tissues, including brain and intracranial tumors.

Original languageEnglish (US)
Pages (from-to)895-907
Number of pages13
JournalTranslational Oncology
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Fenofibrate
Cell Death
Glioblastoma
Solubility
Neoplasms
Respiration
Peroxisome Proliferator-Activated Receptors
Water
Esterases
Blood-Brain Barrier
Brain Neoplasms
Oral Administration
Mitochondria
Esters
Lipids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Stalinska, J., Zimolag, E., Pianovich, N. A., Zapata, A., Lassak, A., Rak, M., ... Reiss, K. (2019). Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential. Translational Oncology, 12(7), 895-907. https://doi.org/10.1016/j.tranon.2019.04.006

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential. / Stalinska, J.; Zimolag, E.; Pianovich, N. A.; Zapata, A.; Lassak, A.; Rak, M.; Dean, M.; Ucar-Bilyeu, D.; Wyczechowska, D.; Culicchia, F.; Marrero, L.; Del Valle, L.; Sarkaria, Jann N; Peruzzi, F.; Jursic, B. S.; Reiss, K.

In: Translational Oncology, Vol. 12, No. 7, 01.07.2019, p. 895-907.

Research output: Contribution to journalArticle

Stalinska, J, Zimolag, E, Pianovich, NA, Zapata, A, Lassak, A, Rak, M, Dean, M, Ucar-Bilyeu, D, Wyczechowska, D, Culicchia, F, Marrero, L, Del Valle, L, Sarkaria, JN, Peruzzi, F, Jursic, BS & Reiss, K 2019, 'Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential', Translational Oncology, vol. 12, no. 7, pp. 895-907. https://doi.org/10.1016/j.tranon.2019.04.006
Stalinska J, Zimolag E, Pianovich NA, Zapata A, Lassak A, Rak M et al. Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential. Translational Oncology. 2019 Jul 1;12(7):895-907. https://doi.org/10.1016/j.tranon.2019.04.006
Stalinska, J. ; Zimolag, E. ; Pianovich, N. A. ; Zapata, A. ; Lassak, A. ; Rak, M. ; Dean, M. ; Ucar-Bilyeu, D. ; Wyczechowska, D. ; Culicchia, F. ; Marrero, L. ; Del Valle, L. ; Sarkaria, Jann N ; Peruzzi, F. ; Jursic, B. S. ; Reiss, K. / Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential. In: Translational Oncology. 2019 ; Vol. 12, No. 7. pp. 895-907.
@article{f0946adcd2704f3e9d26d05dac55878c,
title = "Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential",
abstract = "Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy. We have previously reported that fenofibrate in its unprocessed form (ester)accumulates in the mitochondria, inhibits mitochondrial respiration, and triggers a severe energy deficit and extensive glioblastoma cell death. However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARα agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death. To address these issues, we have made several chemical modifications in fenofibrate structure to increase its stability, water solubility, tissue penetration, and ultimately anticancer potential. Our data show that, in comparison to fenofibrate, four new compounds designated here as PP1, PP2, PP3, and PP4 have improved anticancer activity in vitro. Like fenofibrate, the compounds block mitochondrial respiration and trigger massive glioblastoma cell death in vitro. In addition, one of the lead compounds, PP1, has improved water solubility and is significantly more stable when exposed to human blood in comparison to fenofibrate. Importantly, mice bearing large intracranial glioblastoma tumors demonstrated extensive areas of tumor cell death within the tumor mass following oral administration of PP1, and the treated mice did not show any major signs of distress, and accumulated PP1 at therapeutically relevant concentrations in several tissues, including brain and intracranial tumors.",
author = "J. Stalinska and E. Zimolag and Pianovich, {N. A.} and A. Zapata and A. Lassak and M. Rak and M. Dean and D. Ucar-Bilyeu and D. Wyczechowska and F. Culicchia and L. Marrero and {Del Valle}, L. and Sarkaria, {Jann N} and F. Peruzzi and Jursic, {B. S.} and K. Reiss",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.tranon.2019.04.006",
language = "English (US)",
volume = "12",
pages = "895--907",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "7",

}

TY - JOUR

T1 - Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential

AU - Stalinska, J.

AU - Zimolag, E.

AU - Pianovich, N. A.

AU - Zapata, A.

AU - Lassak, A.

AU - Rak, M.

AU - Dean, M.

AU - Ucar-Bilyeu, D.

AU - Wyczechowska, D.

AU - Culicchia, F.

AU - Marrero, L.

AU - Del Valle, L.

AU - Sarkaria, Jann N

AU - Peruzzi, F.

AU - Jursic, B. S.

AU - Reiss, K.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy. We have previously reported that fenofibrate in its unprocessed form (ester)accumulates in the mitochondria, inhibits mitochondrial respiration, and triggers a severe energy deficit and extensive glioblastoma cell death. However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARα agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death. To address these issues, we have made several chemical modifications in fenofibrate structure to increase its stability, water solubility, tissue penetration, and ultimately anticancer potential. Our data show that, in comparison to fenofibrate, four new compounds designated here as PP1, PP2, PP3, and PP4 have improved anticancer activity in vitro. Like fenofibrate, the compounds block mitochondrial respiration and trigger massive glioblastoma cell death in vitro. In addition, one of the lead compounds, PP1, has improved water solubility and is significantly more stable when exposed to human blood in comparison to fenofibrate. Importantly, mice bearing large intracranial glioblastoma tumors demonstrated extensive areas of tumor cell death within the tumor mass following oral administration of PP1, and the treated mice did not show any major signs of distress, and accumulated PP1 at therapeutically relevant concentrations in several tissues, including brain and intracranial tumors.

AB - Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy. We have previously reported that fenofibrate in its unprocessed form (ester)accumulates in the mitochondria, inhibits mitochondrial respiration, and triggers a severe energy deficit and extensive glioblastoma cell death. However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARα agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death. To address these issues, we have made several chemical modifications in fenofibrate structure to increase its stability, water solubility, tissue penetration, and ultimately anticancer potential. Our data show that, in comparison to fenofibrate, four new compounds designated here as PP1, PP2, PP3, and PP4 have improved anticancer activity in vitro. Like fenofibrate, the compounds block mitochondrial respiration and trigger massive glioblastoma cell death in vitro. In addition, one of the lead compounds, PP1, has improved water solubility and is significantly more stable when exposed to human blood in comparison to fenofibrate. Importantly, mice bearing large intracranial glioblastoma tumors demonstrated extensive areas of tumor cell death within the tumor mass following oral administration of PP1, and the treated mice did not show any major signs of distress, and accumulated PP1 at therapeutically relevant concentrations in several tissues, including brain and intracranial tumors.

UR - http://www.scopus.com/inward/record.url?scp=85065227290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065227290&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2019.04.006

DO - 10.1016/j.tranon.2019.04.006

M3 - Article

VL - 12

SP - 895

EP - 907

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 7

ER -